• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Moderna Set to Join S&P 500

    7/15/21 7:01:00 PM ET
    $SPGI
    $ALXN
    $AZN
    $MRNA
    Finance: Consumer Services
    Finance
    Major Pharmaceuticals
    Health Care
    Get the next $SPGI alert in real time by email

    NEW YORK, July 15, 2021 /PRNewswire/ -- Moderna Inc. (NASD:MRNA) will replace Alexion Pharmaceuticals Inc. (NASD:ALXN) in the S&P 500 effective prior to the opening of trading on Wednesday, July 21. AstraZeneca Plc (LSE:AZN; NASD:AZN) is acquiring Alexion Pharmaceuticals in a deal expected to be completed soon pending final closing conditions.

    Following is a summary of the changes that will take place prior to the open of trading on the effective date:

    Effective Date

    Index Name      

    Action

    Company Name

    Ticker

    GICS Sector

    July 21, 2021

    S&P 500

    Addition

    Moderna

    MRNA

    Health Care



    S&P 500

    Deletion

    Alexion Pharmaceuticals

    ALXN

    Health Care

    For more information about S&P Dow Jones Indices, please visit www.spdji.com

    ABOUT S&P DOW JONES INDICES

    S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.

    S&P Dow Jones Indices is a division of S&P Global (NYSE:SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spdji.com.

    FOR MORE INFORMATION:

    S&P Dow Jones Indices

    [email protected]

    Media Inquiries

    [email protected]

    Cision View original content:https://www.prnewswire.com/news-releases/moderna-set-to-join-sp-500-301335329.html

    SOURCE S&P Dow Jones Indices

    Get the next $SPGI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SPGI
    $ALXN
    $AZN
    $MRNA

    CompanyDatePrice TargetRatingAnalyst
    AstraZeneca PLC
    $AZN
    4/15/2025$75.00Outperform
    Exane BNP Paribas
    S&P Global Inc.
    $SPGI
    4/10/2025$600.00Buy
    BofA Securities
    Moderna Inc.
    $MRNA
    3/13/2025$40.00Neutral
    Citigroup
    S&P Global Inc.
    $SPGI
    3/12/2025$599.00Outperform
    Mizuho
    Moderna Inc.
    $MRNA
    2/18/2025$111.00 → $45.00Overweight → Equal Weight
    Barclays
    AstraZeneca PLC
    $AZN
    2/13/2025Neutral → Buy
    UBS
    AstraZeneca PLC
    $AZN
    2/12/2025Overweight
    Morgan Stanley
    Moderna Inc.
    $MRNA
    1/29/2025$99.00 → $51.00Buy → Neutral
    Goldman
    More analyst ratings

    $SPGI
    $ALXN
    $AZN
    $MRNA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Bancel Stephane bought $5,004,318 worth of shares (160,314 units at $31.22) (SEC Form 4)

      4 - Moderna, Inc. (0001682852) (Issuer)

      3/4/25 4:27:16 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Sagan Paul bought $1,004,251 worth of shares (31,620 units at $31.76) (SEC Form 4)

      4 - Moderna, Inc. (0001682852) (Issuer)

      3/4/25 4:24:36 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Jacoby Rebecca bought $8,971 worth of shares (69 units at $130.01), increasing direct ownership by 17% to 469 units (SEC Form 4)

      4 - S&P Global Inc. (0000064040) (Issuer)

      6/17/24 4:04:40 PM ET
      $SPGI
      Finance: Consumer Services
      Finance

    $SPGI
    $ALXN
    $AZN
    $MRNA
    Leadership Updates

    Live Leadership Updates

    See more
    • Pegasystems Set to Join S&P MidCap 400

      NEW YORK, May 19, 2025 /PRNewswire/ -- Pegasystems Inc. (NASD: PEGA) will replace Nordstrom Inc. (NYSE:JWN) in the S&P MidCap 400 effective prior to the opening of trading on Thursday, May 22. The Nordstrom family and El Puerto de Liverpool S.A.B. de C.V. (BMV:LIVEPOL) are acquiring Nordstrom in a deal expected to be completed on May 20. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector May 22, 2025 S&P MidCap 400 Addition Pegasystems PEGA Information Technology May 22, 2025 S&P MidCap 400 Deletion Nordstrom JWN Consumer Discretionary For more information abou

      5/19/25 6:17:00 PM ET
      $JWN
      $PEGA
      $SPGI
      Clothing/Shoe/Accessory Stores
      Consumer Discretionary
      EDP Services
      Technology
    • Coinbase Global Set to Join S&P 500

      NEW YORK, May 12, 2025 /PRNewswire/ -- Coinbase Global Inc. (NASD: COIN) will replace Discover Financial Services (NYSE:DFS) in the S&P 500 effective prior to the opening of trading on Monday, May 19. S&P 500 constituent Capital One Financial Corp. (NYSE:COF) is acquiring Discover Financial Services in a deal expected to be completed soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector May 19, 2025 S&P 500 Addition Coinbase Global COIN Financials May 19, 2025 S&P 500 Deletion Discover Financial Services DFS Financials For m

      5/12/25 6:00:00 PM ET
      $COF
      $COIN
      $DFS
      $SPGI
      Major Banks
      Finance
      Finance: Consumer Services
    • Ted Myles Joins Cellarity as Chief Executive Officer

      Myles, a Biopharma Industry Veteran, Will Also Join Flagship Pioneering as a CEO-Partner CAMBRIDGE, Mass., May 12, 2025 /PRNewswire/ -- Cellarity, a life sciences company transforming the way medicines are created, and Flagship Pioneering, the bioplatform innovation company, today announced the appointment of Ted Myles as Chief Executive Officer of Cellarity and CEO-Partner at Flagship. Myles is a seasoned biopharma leader with deep experience and a track record for building clinical and commercial-stage companies. Previously, he was Chief Financial Officer and Chief Operating

      5/12/25 8:00:00 AM ET
      $FHTX
      $MRNA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $SPGI
    $ALXN
    $AZN
    $MRNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $SPGI
    $ALXN
    $AZN
    $MRNA
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $SPGI
    $ALXN
    $AZN
    $MRNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $SPGI
    $ALXN
    $AZN
    $MRNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Exane BNP Paribas initiated coverage on AstraZeneca with a new price target

      Exane BNP Paribas initiated coverage of AstraZeneca with a rating of Outperform and set a new price target of $75.00

      4/15/25 12:40:56 PM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BofA Securities resumed coverage on S&P Global with a new price target

      BofA Securities resumed coverage of S&P Global with a rating of Buy and set a new price target of $600.00

      4/10/25 8:19:38 AM ET
      $SPGI
      Finance: Consumer Services
      Finance
    • Citigroup initiated coverage on Moderna with a new price target

      Citigroup initiated coverage of Moderna with a rating of Neutral and set a new price target of $40.00

      3/13/25 8:15:14 AM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ENHERTU® Reduced the Risk of Death by 30% Versus Ramucirumab Plus Paclitaxel as a Second-Line Therapy in Patients with HER2 Positive Unresectable or Metastatic Gastric Cancer in DESTINY-Gastric04 Phase 3 Trial

      Daiichi Sankyo and AstraZeneca's ENHERTU demonstrated a median overall survival of 14.7 months Results reinforce second-line use of ENHERTU globally in this setting Positive results from the DESTINY-Gastric04 phase 3 trial showed ENHERTU® (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared to ramucirumab plus paclitaxel in patients with second-line HER2 positive (IHC 3+ or IHC 2+/ISH+) unresectable and/or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. Results will be presented today as a late-breaking oral presentation (LBA #4002) at the 2025 American Society of Clinical Oncol

      5/31/25 8:00:00 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Danaher Announces Diagnostic Development and Commercialization Partnership to Scale Precision Medicine

      Danaher has entered a partnership with AstraZeneca to scale precision medicine, including developing the next generation of AI-powered diagnosticsThis partnership aims to create a framework for rapid diagnostics research, development and commercialization Danaher, through its Centers for Enabling Precision Medicine, will provide support in all aspects of the development cycle across diagnostic modalitiesWASHINGTON, May 29, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) ("Danaher"), a global science and technology innovator, announced today the launch of a partnership with AstraZeneca (NASDAQ:AZN) to develop and commercialize novel diagnostic tools and tests intended to help clinicians b

      5/29/25 4:30:00 PM ET
      $AZN
      $DHR
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Industrial Machinery/Components
      Industrials
    • S&P Global Expands Collaboration with Databricks with the addition of S&P Capital IQ Pro datasets via Delta Sharing

      Additional S&P Global datasets available via Databricks Delta Sharing include financials, estimates, filings, transcripts, transactions, sustainability and more NEW YORK, May 28, 2025 /PRNewswire/ -- S&P Global (NYSE:SPGI) announced today the addition of several S&P Capital IQ Pro datasets available in Databricks. Powered by Databricks Delta Sharing, this enhanced collaboration between S&P Global and Databricks, the data and AI company, allows users to directly access and query a wide array of additional S&P Global datasets, including financials, estimates, filings, transcripts, transactions, sustainability across investment management, risk, and competitive intelligence use cases — all with

      5/28/25 8:30:00 AM ET
      $SPGI
      Finance: Consumer Services
      Finance
    • SEC Form SC 13G/A filed by Moderna Inc. (Amendment)

      SC 13G/A - Moderna, Inc. (0001682852) (Subject)

      4/10/24 2:03:52 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by S&P Global Inc. (Amendment)

      SC 13G/A - S&P Global Inc. (0000064040) (Subject)

      2/13/24 5:13:53 PM ET
      $SPGI
      Finance: Consumer Services
      Finance
    • SEC Form SC 13G/A filed by Moderna Inc. (Amendment)

      SC 13G/A - Moderna, Inc. (0001682852) (Subject)

      2/7/24 8:42:56 AM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Mock James M converted options into 1,101 shares and covered exercise/tax liability with 533 shares, increasing direct ownership by 4% to 16,191 units (SEC Form 4)

      4 - Moderna, Inc. (0001682852) (Issuer)

      5/29/25 5:16:01 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Legal Officer Klinger Shannon Thyme converted options into 1,101 shares and covered exercise/tax liability with 533 shares, increasing direct ownership by 2% to 26,180 units (SEC Form 4)

      4 - Moderna, Inc. (0001682852) (Issuer)

      5/29/25 5:13:23 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President Hoge Stephen converted options into 2,046 shares and covered exercise/tax liability with 990 shares, increasing direct ownership by 0.07% to 1,451,783 units (SEC Form 4)

      4 - Moderna, Inc. (0001682852) (Issuer)

      5/29/25 5:09:36 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SPGI
    $ALXN
    $AZN
    $MRNA
    SEC Filings

    See more
    • SEC Form 6-K filed by AstraZeneca PLC

      6-K - ASTRAZENECA PLC (0000901832) (Filer)

      5/27/25 6:09:42 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by AstraZeneca PLC

      6-K - ASTRAZENECA PLC (0000901832) (Filer)

      5/23/25 8:56:02 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by AstraZeneca PLC

      6-K - ASTRAZENECA PLC (0000901832) (Filer)

      5/21/25 9:41:09 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPGI
    $ALXN
    $AZN
    $MRNA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • November 30, 2020 - Coronavirus (COVID-19) Update: FDA Announces Advisory Committee Meeting to Discuss Second COVID-19 Vaccine Candidate

      For Immediate Release: November 30, 2020 The U.S. Food and Drug Administration has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Dec. 17 to discuss the request for emergency use authorization (EUA) for a COVID-19 vaccine from Moderna, Inc. “In keeping with the FDA’s commitment to ensuring full transparency, dialogue and efficiency, the Vaccines and Related Biological Products Advisory Comm

      11/30/20 5:12:14 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SPGI
    $ALXN
    $AZN
    $MRNA
    Financials

    Live finance-specific insights

    See more
    • S&P Dow Jones Indices Announces Change to the S&P/TSX Canadian Dividend Aristocrats Index

      TORONTO, May 23, 2025 /CNW/ - S&P Dow Jones Indices announces the following index change to the S&P/TSX Canadian Dividend Aristocrats Index as a result of the monthly dividend review. Change will be effective prior to the open of trading on Monday, June 2, 2025. S&P/TSX Canadian Dividend Aristocrats Index – June 2, 2025 Symbol COMPANY DELETED BCE BCE Inc DELETED FSZ Fiera Capital Corporation For more information about S&P Dow Jones Indices, please visit www.spdji.com ABOUT S&P DOW JONES INDICES S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Indu

      5/23/25 5:15:00 PM ET
      $SPGI
      Finance: Consumer Services
      Finance
    • S&P Global Declares Second Quarter Dividend

      NEW YORK, May 6, 2025 /PRNewswire/ -- The Board of Directors of S&P Global (NYSE:SPGI) has approved a cash dividend on the Corporation's common stock for the second quarter of 2025. The dividend of $0.96 is payable on June 11, 2025, to shareholders of record on May 28, 2025. The annualized dividend rate is $3.84 per share. The Company has paid a dividend each year since 1937 and is one of fewer than 30 companies in the S&P 500® that has increased its dividend annually for more than 50 years. About S&P Global: S&P Global (NYSE:SPGI) provides essential intelligence. We enable governments, businesses and individuals with the right data, expertise and connected technology so that they can make

      5/6/25 4:39:00 PM ET
      $SPGI
      Finance: Consumer Services
      Finance
    • S&P Global Announces Intent to Separate Mobility Segment into Standalone Public Company

      S&P Global Strongly Positioned to Drive Continued Profitable Growth and Value Creation Across Four Core BusinessesS&P Global Mobility to Be an Automotive Data and Technology Leader with Flexibility to Pursue Near- and Long-Term Growth OpportunitiesCompany Separately Reports First Quarter 2025 Results; Conference Call Today at 8:30 a.m. ETNEW YORK, April 29, 2025 /PRNewswire/ -- S&P Global (NYSE:SPGI) today announced its intent to separate S&P Global Mobility ("Mobility") from S&P Global to drive long-term value creation. The planned separation is expected to result in Mobility becoming a standalone public company.

      4/29/25 7:22:00 AM ET
      $SPGI
      Finance: Consumer Services
      Finance